Exploring Novel Treatment Options for Interstitial Pulmonary Fibrosis and Progressive Pulmonary Fibrosis : Episode 18

The Future of Pulmonary Fibrosis Management: Precision Medicine, Biomarkers and AI

April 10, 2025

Opinion

Video

Eric Cannon, PharmD, FAMCP, discusses how precision medicine advancements and biomarker development can enable targeted idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) therapies by identifying patient subgroups most likely to benefit from specific interventions. Artificial intelligence (AI) integration offers potential for earlier diagnosis, improved prognostication and personalized treatment optimization through data pattern recognition.

EP: 1.Distinguishing Between the Different Interstitial Lung Diseases

EP: 2.Mortality Rates and Comorbidities Associated With Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

EP: 3.Epidemiology and Economic Burden of IPF and PPF

EP: 4.Best Practices in Diagnosis of IPF and PPF

EP: 5.The Role of Biomarkers and Biopsy for IPF and PPF

EP: 6.Key Unmet Needs in IPF and PPF

EP: 7.The Role of Corticosteroids in Managing Pulmonary Fibrosis

EP: 8.Exploring Nintedanib and Pirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis

EP: 9.Monitoring for and Managing the Adverse Events Associated With Antifibrotic Agents

EP: 10.Nonpharmacological Management Options for Patients With Pulmonary Fibrosis

EP: 11.Guideline Recommendations for the Treatment of Pulmonary Fibrosis

EP: 12.Unmet Needs in the Treatment Guidelines for Pulmonary Fibrosis

EP: 13.Treatment Algorithms and Insurance Coverage for Pulmonary Fibrosis

EP: 14.The Future of Treatment Approaches for Pulmonary Fibrosis

EP: 15.Bridging gaps in pulmonary fibrosis management: Insights into diagnosis, treatment and future directions

EP: 16.The PDE4B Pathway: Exploring Nerandomilast’s Potential in Pulmonary Fibrosis Treatment

EP: 17.LPA1 Modulation: Admilparant’s Role in the Evolution of IPF and PPF Therapies

Now Viewing

EP: 18.The Future of Pulmonary Fibrosis Management: Precision Medicine, Biomarkers and AI

Video content above is prompted by the following:

How can advancements in precision medicine and biomarker development improve treatment strategies for pulmonary fibrosis?
How do you envision AI impacting management strategies of patients with IPF and PPF?

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!